2510-32-9

Basic information

• Product Name: 4-METHYL-1,3-OXAZOLE-5-CARBOXYLIC ACID
• Synonyms: 4-METHYL-5-OXAZOLECARBOXYLIC ACID;4-METHYL-OXAZOLE-5-CARBOXYLIC ACID;4-METHYL-1,3-OXAZOLE-5-CARBOXYLIC ACID;4-Methyl-1,3-oxazole-5-carboxylic acid 95%;4-Methyl-1,3-oxazole-5-carboxylic acid ,97%;4-methyl-1,3-oxazole-5-carboxylic acid(SALTDATA: FREE);4-Methyl-oxazol-5-carboxylic acid;5-Oxazolecarboxylic acid, 4-Methyl-
• CAS NO: 2510-32-9
• Molecular Formula: C₅H₅NO₃
• Molecular Weight: 127.1
• Product Categories: Carboxylic Acids;Oxazoles, Isoxazoles & Benzoxazoles;Heterocyclic Compounds;Carboxylic Acids;Oxazoles, Isoxazoles & Benzoxazoles;Building Blocks;Heterocyclic Building Blocks;Oxazoles
• Mol File: 2510-32-9.mol
• Article Data: 15

Chemical Properties

• Melting Point: 239 °C
• Boiling Point: 267.3 °C at 760 mmHg
• Flash Point: 115.5 °C
• Appearance: white powder
• Density: 1.348 g/cm³
• Vapor Pressure: 0.00408mmHg at 25°C
• Refractive Index: 1.514
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 2.09±0.31(Predicted)
• CAS DataBase Reference: 4-METHYL-1,3-OXAZOLE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHYL-1,3-OXAZOLE-5-CARBOXYLIC ACID(2510-32-9)
• EPA Substance Registry System: 4-METHYL-1,3-OXAZOLE-5-CARBOXYLIC ACID(2510-32-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36/37/38
• Safety Statements: 22-26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 2510-32-9(Hazardous Substances Data)

Usage

Chemical Properties

White to tan solid

Uses

Different sources of media describe the Uses of 2510-32-9 differently. You can refer to the following data:
1. 4-Methoxyoxazole-5-carboxylic Acid is used in the synthesis of highly selective α4β2-Nicotinic acetylcholine receptor agonists used in the treatment of cognitive disorders. It is also used in the synthesis of small molecule human FPR1 receptor antagonists.
2. Used in a palladium-catalyzed cross-coupling between heteroaryl carboxylic acids and aryl bromides leading to arylated heterocycles.

InChI:InChI=1/C5H5NO3/c1-3-4(5(7)8)9-2-6-3/h2H,1H3,(H,7,8)

Upstream product

• 77287-34-4 formamide 
• 18632-42-3 2-acetoxy-acetoacetic acid ethyl ester 
• 20485-39-6 ethyl 4-methyloxazole-5-carboxylate 
• 609-15-4 ethyl 2-chloro-3-oxo-butyrate 

Downstream Products

• 1008-29-3 4-methyl-5-phenyl-1,3-oxazole 
• 693-93-6 4-methyloxazole 
• 3403-45-0 tert-butyl (4-methyloxazol-5-yl)carbamate 
• 1192575-89-5 N-hydroxy-1-(4-methyl-1,3-oxazol-5-yl)-1-phenylmethanimine 
• 162818-61-3 (4-methyl-1,3-oxazol-5-yl)(phenyl)methanone 

Relevant articles and documents

Widely Exploited, Yet Unreported: Regiocontrolled Synthesis and the Suzuki–Miyaura Reactions of Bromooxazole Building Blocks

An approach to synthesis of 2-, 4-, and 5-bromooxazoles is described. The method was optimized, and its scope was extended to all three isomeric parents, as well as various alkyl- and aryl-substituted bromooxazoles. It was found that direct regiocontrolled lithiation followed by reaction with electrophilic bromine source was common for all substrates and led exclusively to the target substituted 2-, 4- and 5-bromooxazoles on multigram scale. The utility of the multipurpose building blocks obtained in this work was demonstrated in the Suzuki–Miyaura cross-coupling reaction under parallel synthesis conditions.

DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

Method for synthesizing furanosteroids

The present invention is a method for synthesizing furanosteroids. The method involves intramolecular Diels-Alder/retro-Diels-Alder reaction and tautomerization of a functionalized alkyne oxazole to produce a furo[2,3-b]phenol derivative which is elaborated by intermolecular and intramolecular condensations to generate ring-A of the furanosteroid. Furanosteroids and pharmaceutical compositions containing the same are also provided.